The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Cleveland HeartLab pulled in $14.7 million in equity financing for its proprietary test for cardiac inflammation, according to a regulatory filing.
The CardioMPO test was developed by Dr. Stanley Hazen, director of the Cleveland Clinic’s center for cardiovascular diagnostics and prevention.
Cleveland HeartLab closed a $3 million round in 2010, with backers including Glengary and Second Generation Ltd.
Neoprobe Corp. (NYSE Amex:NEOP) is getting a new chief executive and, perhaps, a new board member.
The Dublin, Ohio-based cancer diagnostics firm announced that CEO David Bupp will be replaced by chief development officer Mark Pykett on April 15.
By Mary Vanac
Jake Orville always thought the cardiac inflammation biomarker developed by Dr. Stanley Hazen and his colleagues at the Cleveland Clinic was a valuable and proven technology. But his efforts to make it a commercial success for spinoff company PrognostiX failed, largely due to the difficulty of getting the test through clinical trial process required by the Food & Drug Administration.
